Cited by Predictive Factors of Antibody–Drug Conjugate Treatment in Metastatic Breast Cancer: A Narrative Review

Predictive Factors of Antibody–Drug Conjugate Treatment in Metastatic Breast Cancer: A Narrative Review DOI

et al.

Cancers, Journal Year: 2024, Volume and Issue: 16(23), P. 4082 - 4082

Published: Dec. 5, 2024

Antibody-drug conjugates (ADCs) have revolutionized the treatment landscape for metastatic breast cancer, offering targeted delivery of cytotoxic agents with improved efficacy and tolerability compared to conventional chemotherapy. This narrative review explores key predictive factors influencing ADCs, focusing on HER2-targeted therapies, such as trastuzumab emtansine deruxtecan, well sacituzumab govitecan triple-negative cancer. HER2 expression, TROP-2 levels, hormone receptor status, tumor microenvironment emerge critical biomarkers patient selection therapeutic outcomes. Additionally, we discuss resistance mechanisms, antigen loss, impaired drug internalization, role circulating DNA in predicting ADC response. Finally, future perspectives sequential use ADCs potential combination therapies are highlighted, along emerging targeting alternative antigens like HER3 LIV-1. Overall, identifying overcoming mechanisms essential optimizing thereby improving

Language: Английский

Beyond failure of endocrine-based therapies in HR+/HER2 negative advanced breast cancer: what before chemotherapy? A glimpse into the future. DOI

Rosalba Torrisi, R. Gerosa, Chiara Miggiano

et al.

Critical Reviews in Oncology/Hematology, Journal Year: 2025, Volume and Issue: 208, P. 104634 - 104634

Published: Feb. 1, 2025

Language: Английский

Citations

Antibody-drug conjugates in breast cancer treatment: resistance mechanisms and the role of therapeutic sequencing DOI

Éric Larose,

Xinying Hua,

Silin Yu

et al.

Cancer Drug Resistance, Journal Year: 2025, Volume and Issue: unknown

Published: March 6, 2025

Antibody-drug conjugates (ADCs) are a transformative approach in breast cancer therapy, offering targeted treatment with reduced toxicity by selectively delivering cytotoxic agents to cells. While ADCs like trastuzumab emtansine (T-DM1), deruxtecan (T-DXd), and sacituzumab govitecan have shown significant efficacy, resistance mechanisms such as antigen loss, impaired internalization, efflux of payloads challenge their effectiveness. This review discusses these explores advanced strategies overcome them, including innovations linker chemistry, multi-antigen targeting, biomarker-driven personalization. Additionally, therapeutic sequencing - determining the optimal order other treatments chemotherapy, endocrine immunotherapy is examined crucial maximize ADC efficacy manage resistance. Evidence-based strategies, particularly for human epidermal growth factor receptor 2 (HER2)-positive triple-negative (TNBC), supported clinical trials demonstrating benefits both early-stage metastatic settings. The potential combination therapies, immune checkpoint inhibitors (ICIs), further highlights evolving landscape treatment. As technology advances, personalized approaches integrating biomarkers optimized protocols offer promising avenues enhance outcomes combat cancer.

Language: Английский

Citations

Antibody–Drug Conjugates (ADCs): current and future biopharmaceuticals DOI